Cogent Biosciences, Inc. Common Stock (COGT) Stock Price

COGTStock

$29.52+80.44%52W

Market Cap$5.12B

P/E—

PEG Ratio—

Div yield—

Beta0.35

COGT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-29.01%

Price vs S&P 500 (4W)-6.42%

VGM Score39.04

Book Value / Share (Quarterly)$3.10

P/TBV (Annual)2.25x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.80

Price vs S&P 500 (YTD)-28.82%

Net Profit Margin (TTM)-264.08%

EPS (TTM)$-2.44

10-Day Avg Trading Volume2.46M

EPS Excl Extra (TTM)$-2.44

EPS (Annual)$-2.46

ROI (Annual)-99.89%

Net Profit Margin (5Y Avg)-407.35%

Cash / Share (Quarterly)$4.62

ROA (Last FY)-78.07%

EBITD / Share (TTM)$-2.54

ROE (5Y Avg)-59.00%

Operating Margin (TTM)-295.77%

Cash Flow / Share (Annual)$-1.65

P/B Ratio9.62x

P/B Ratio (Quarterly)12.42x

Net Income / Employee (Annual)$-992,200

EV / Revenue (TTM)223.00x

ROA (TTM)-48.65%

EPS Incl Extra (Annual)$-2.46

Current Ratio (Annual)14.23x

Quick Ratio (Quarterly)13.36x

3-Month Avg Trading Volume2.28M

52-Week Price Return80.44%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.52

P/S Ratio (Annual)650.88x

Asset Turnover (Annual)0.03x

52-Week High$43.73

Operating Margin (5Y Avg)-434.04%

EPS Excl Extra (Annual)$-2.46

CapEx CAGR (5Y)80.39%

Tangible BV CAGR (5Y)55.30%

26-Week Price Return-19.10%

Quick Ratio (Annual)14.08x

13-Week Price Return-24.46%

Total Debt / Equity (Annual)0.35x

Current Ratio (Quarterly)13.57x

Enterprise Value$5.16B

Asset Turnover (TTM)0.36x

Book Value / Share Growth (5Y)-11.46%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-950.57%

Cash / Share (Annual)$5.60

3-Month Return Std Dev45.66%

Net Income / Employee (TTM)$-1,461,900

ROE (Last FY)-99.89%

EPS Basic Excl Extra (Annual)$-2.46

Receivables Turnover (TTM)7.87x

Total Debt / Equity (Quarterly)0.42x

EPS Incl Extra (TTM)$-2.44

Receivables Turnover (Annual)7.87x

ROI (TTM)-54.02%

P/S Ratio (TTM)221.18x

Pretax Margin (5Y Avg)-407.35%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.66

Price vs S&P 500 (52W)64.91%

Year-to-Date Return-16.89%

5-Day Price Return-0.87%

EPS Normalized (Annual)$-2.46

ROA (5Y Avg)-49.41%

Net Profit Margin (Annual)-950.57%

Month-to-Date Return-7.81%

Cash Flow / Share (TTM)$-2.32

EBITD / Share (Annual)$-2.63

Operating Margin (Annual)-1044.47%

LT Debt / Equity (Annual)0.35x

ROI (5Y Avg)-59.00%

LT Debt / Equity (Quarterly)0.42x

EPS Basic Excl Extra (TTM)$-2.44

P/TBV (Quarterly)1.90x

P/B Ratio (Annual)8.49x

Pretax Margin (TTM)-264.08%

Book Value / Share (Annual)$3.95

Price vs S&P 500 (13W)-27.15%

Beta0.35x

P/FCF (Annual)325.65x

Revenue / Share (TTM)$0.00

ROE (TTM)-72.57%

52-Week Low$13.78

vGradeF

mGradeB

vgmGradeD

COGT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.56	-$0.52	+7.96%(+$0.04)
Q1 2026	May 5, 2026	-$0.54	-$0.53	+1.88%(+$0.01)
Q4 2025	Feb 17, 2026	-$0.51	-$0.56	-10.51%(-$0.05)
Q3 2025	Nov 7, 2025	-$0.52	-$0.50	+3.24%(+$0.02)
Q2 2025	Aug 5, 2025	-$0.58	-$0.53	+7.91%(+$0.05)

COGT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.26

4.33

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
COGTCogent Biosciences, Inc. Common Stock	F	—	B	221.2x	—	—	—	$29.52
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Cogent Biosciences, Inc. Common Stock

Cogent Biosciences develops precision therapies for genetically defined diseases. Its lead program, CGT9486, is a selective tyrosine kinase inhibitor targeting KIT mutations—specifically D816V mutations that drive Systemic Mastocytosis and exon 17 mutations found in advanced gastrointestinal stromal tumors (GIST). The company addresses significant unmet medical needs in these serious hematologic and oncologic conditions.

COGT Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.55

Revenue estimate$0

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

COGT Insider Transactions

SellAug 27, 2026
MORRIS ARLENE M.
Director
Shares: 45,510Value: $1.69M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

BCPCBalchem CorporationChemicals
KODKodiak Sciences Inc Common StockBiological Products
CGONCG Oncology, Inc. Common stockBiological Products
CECelanese Corporation Common StockPlastics & Synthetics
MEOHMethanex CorpIndustrial Chemicals
SRRKScholar Rock Holding Corporation Common StockBiological Products
CRSPCRISPR Therapeutics AGBiological Products
RGCRegencell Bioscience Holdings Limited Ordinary SharesPharmaceutical Preparations

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$13.78

High$43.73